tiprankstipranks
KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
Holding DE:4XC1?
Track your performance easily

KalVista Pharmaceuticals (4XC1) Income Statement

0 Followers

KalVista Pharmaceuticals Income Statement

Last quarter (Q1 2025), KalVista Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, KalVista Pharmaceuticals's net income was $-40.44M. See KalVista Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Apr 24Apr 23Apr 22Apr 21Apr 20
Total Revenue
-----$ 12.69M
Cost of Revenue
------
Gross Profit
-----$ 12.69M
Operating Expense
$ 155.57M$ 140.44M$ 110.87M$ 96.61M$ 57.92M$ 53.22M
Operating Income
$ -155.57M$ -140.44M$ -110.87M$ -96.61M$ -57.92M$ -40.53M
Net Non Operating Interest Income Expense
$ 4.67M$ 3.90M$ 2.23M$ 1.09M$ 903.00K$ 1.83M
Other Income Expense
$ -8.94M$ -9.77M$ -15.64M$ 13.18M$ -9.93M$ -9.83M
Pretax Income
$ -141.77M$ -126.64M$ -92.91M$ -82.34M$ -46.24M$ -29.24M
Tax Provision
-----$ -124.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -141.77M$ -126.64M$ -92.91M$ -82.34M$ -46.24M$ -29.12M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 155.57M$ 140.44M$ 110.87M$ 96.61M$ 57.92M$ 53.22M
Net Income From Continuing And Discontinued Operation
$ -141.77M$ -126.64M$ -92.91M$ -82.34M$ -46.24M$ -29.12M
Normalized Income
$ -112.98M$ -125.38M-$ -65.05M$ -36.53M-
Interest Expense
------
EBIT
$ -147.99M$ -126.64M$ -92.91M$ -96.61M$ -46.24M$ -29.24M
EBITDA
$ -147.15M$ -125.75M$ -91.22M$ -96.05M$ -45.06M$ -28.54M
Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis